Maja Arnež

Ljubljana University Medical Centre, Lubliano, Ljubljana, Slovenia

Are you Maja Arnež?

Claim your profile

Publications (4)10.53 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: A 13-year-old boy who presented with a red left eye, painful eye movement, blurred vision, photophobia and increased lacrimation, was diagnosed with 1-sided panuveitis with optic disk edema. Diagnostic work-up revealed borrelial antibodies in serum. Diagnosis of Lyme borreliosis was substantiated by demonstration of lymphocytic pleocytosis, intrathecal borrelial antibody synthesis, improvement after treatment with ceftriaxone and exclusion of other causes.
    The Pediatric Infectious Disease Journal 01/2015; 34(1):102-4. DOI:10.1097/INF.0000000000000473 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare clinical effectiveness and safety of treatment with clarithromycin and amoxicillin in children with solitary erythema migrans (EM). Consecutive patients younger than 15 years, referred to our institution in 2004 and 2005 with previously untreated solitary erythema migrans, were included in this prospective study. Basic demographic features and clinical data were collected by means of a questionnaire. The efficiency of treatment of acute disease, development of later major and/or minor manifestations of Lyme borreliosis (LB), and side effects of treatment were surveyed by follow-up visits during the first year after the initiation of antibiotic treatment. The study included 68 female and 67 male children patients. The median age of the patients was 6.5 years. Out of 135 patients, 66 received clarithromycin and 69 amoxicillin. Before treatment no differences in demographic and clinical characteristics between the two groups were observed. The mean duration of EM after the beginning of treatment was 4 days in both groups. Associated symptoms during treatment were present for 7 days in patients treated with clarithromycin and for 10 days in patients receiving amoxicillin (p = 0.188). Minor manifestations of LB were identified in 11 (22.0 %) of 50 patients receiving clarithromycin, and in 16 (29.6 %) of 54 patients receiving amoxicillin who remained in the study during the entire observation period. Major manifestations of LB were not identified in any patient treated with clarithromycin, while there were 2 (3.7 %) patients with major manifestations of LB, who were receiving amoxicillin. Side effects of treatment were identified in 24.2 % patients receiving clarithromycin and 28.1 % patients treated with amoxicillin (p = 0.761). Presence of the Jarisch-Herxheimer's reaction at the beginning of treatment was comparable in both groups (10.6 % and 10.3 %;p = 0.823). Clarithromycin and amoxicillin are equally effective and safe in treatment of children with solitary EM and have comparable side effects.
    Wiener klinische Wochenschrift 07/2012; 124(13-14):427-33. DOI:10.1007/s00508-012-0194-1 · 0.79 Impact Factor
  • Maja Arnež, Eva Ružić-Sabljić
    [Show abstract] [Hide abstract]
    ABSTRACT: To establish the frequency and characteristics of Borrelia burgdorferi sensu lato bacteremia in Slovenian children with solitary and multiple erythema migrans, 1164 patients were included in this prospective study. Bacteremia was established in 11.4% of all patients, 15.8% of patients with multiple erythema migrans, and in 7.6% of patients with solitary erythema migrans. Bacteremia can be detected in children, with untreated erythema migrans, up to 39 days after the onset of skin rash.
    The Pediatric Infectious Disease Journal 06/2011; 30(11):988-90. DOI:10.1097/INF.0b013e318225b8c3 · 3.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present a case of clinically overt acute myositis associated with the initial phase of tick-borne encephalitis in a ten-year-old boy. The diagnosis of the disease was confirmed by detection of tick-borne encephalitis virus RNA in blood prior to the development of serum specific antibodies and the second phase of the disease.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 06/2011; 51(4):276-8. DOI:10.1016/j.jcv.2011.05.021 · 3.47 Impact Factor